Welcome to our dedicated page for Bruker news (Ticker: BRKR), a resource for investors and traders seeking the latest updates and insights on Bruker stock.
Bruker Corporation (Nasdaq: BRKR) regularly issues news and updates on its activities in scientific instruments, diagnostics, superconducting technologies, and advanced research collaborations. This news page aggregates company press releases and third-party coverage so readers can review developments affecting Bruker’s analytical instruments, diagnostic solutions, and related businesses.
Recent announcements highlight multi-year orders in the Bruker Energy & Supercon Technologies (BEST) division for high-performance superconductors used in MRI magnets, including materials that support helium-free MRI magnet architectures. News items also cover orders for high-field NMR and EPR systems from leading European research institutions for materials science, battery research, and disease biology, illustrating how Bruker’s magnetic resonance systems are deployed in academic and government research environments.
Bruker’s news flow also reflects its expansion in applied mass spectrometry and diagnostics. The company has reported the consolidation of full ownership of TOFWERK AG, adding ultra-fast time-of-flight mass spectrometry for real-time air and semiconductor cleanroom monitoring, atmospheric chemistry research, exposomics, and food, flavors and fragrances testing. It has also been associated with the acquisition of AST Revolution, an in vitro diagnostics company focused on rapid antimicrobial susceptibility testing (AST) solutions built around the WAVE and Arc systems.
Investors and researchers following BRKR news can expect updates on earnings releases and financial guidance, capital structure developments such as preferred stock offerings and dividends, board and governance changes, and strategic transactions. This page is a convenient entry point for tracking how Bruker’s instruments, diagnostics, and superconducting technologies are being adopted across life sciences, applied markets, industrial and cleantech research, and semiconductor-related applications.
Bruker (Nasdaq: BRKR) BEST division announced two multi-year supply agreements with two global healthcare OEMs totaling approximately $500 million in expected future BEST revenues, with one agreement extending up to seven years. The expanded framework agreements cover delivery of Bruker’s high-performance niobium-titanium-copper composite superconductors for next-generation MRI magnets, primarily to production sites in the United States and United Kingdom. Bruker said its superconductors support novel helium-free MRI magnet architectures and meet demanding field stability and homogeneity requirements while leveraging manufacturing sites in Europe and the US.
Bruker (NASDAQ: BRKR) acquired an additional 60% of TOFWERK AG, consolidating ownership to 100% and expanding Bruker’s mass spectrometry portfolio into applied small‑molecule markets. TOFWERK, based in Thun, Switzerland, is profitable, employs 130 people, has >b>1,000 instruments worldwide, and reported 2025 revenue of ~$40 million. TOFWERK will operate as a distinct brand, preserving Swiss R&D and OEM partnerships; financial terms were not disclosed.
Bruker Corporation (Nasdaq: BRKR) will participate in the 45th annual J.P. Morgan Healthcare Conference in San Francisco. Senior leadership will present on Monday, January 12, 2026 at 9:00 AM Pacific Time. A live audio webcast will be available on the company's Investor Relations website and a replay will be posted in the Events & Presentations section and remain available for 30 days after the presentation.
RI Research Instruments (BRKR) announced approximately €35 million of orders to supply key components and enabling subsystems for the gamma-ray source at ELI-NP in Romania, with major deliveries expected in late 2026. The scope covers expansion of an existing linac, beam-guiding and focusing components, a linac upgrade to increase pulse rate by 200x, and an optical resonator that amplifies the laser by more than 900x developed with LICOS (TUM spin-out).
The system will produce high-flux, monochromatic, energy-tunable gamma rays (1–20 MeV) via inverse Compton scattering to support advanced nuclear and fundamental research.
Bruker (Nasdaq: BRKR) announced approximately $25 million of orders for high-performance magnetic resonance systems from three European research institutions, with revenue recognition expected over fiscal 2026 and 2027.
Orders include a novel NMR relaxometry system for École Normale Supérieure (ENS-PSL) to complement a 900 MHz spectrometer, two 800 MHz and one 100 MHz systems plus an E580 EPR spectrometer for Max Planck Institute for Solid-State Research focused on battery materials, and an ultra-high field 1 GHz NMR system for Institut Européen de Chimie et Biologie (IECB) as Bordeaux’s flagship platform. Separately, a second 1.2 GHz NMR system was accepted at the University of Birmingham in Q4 2025.
Bruker (Nasdaq: BRKR) said it has appointed diagnostics executive Jack J. Phillips to its board of directors, effective January 1, 2026. Mr. Phillips brings more than 30 years of leadership in diagnostics, including roles as President & CEO of Accelerate Diagnostics (2020–2025) and President & CEO of Roche Diagnostics North America (2010–2020).
Bruker highlighted Phillips' experience in rapid antibiotic susceptibility testing, clinical chemistry, immunodiagnostics, molecular and point-of-care diagnostics, and digital pathology, and said his expertise aligns with Bruker's focus on expanding its infectious disease diagnostics portfolio and leveraging disease-biology research tools for specialty diagnostics.
AST Revolution was announced as sold to Bruker (Nasdaq: BRKR, BRKRP) on November 24, 2025. Financial terms were not disclosed. AST Revolution launched in August 2025 after a court-approved acquisition of select assets of Accelerate Diagnostics under Chapter 11, and the deal includes the WAVE™ and Arc™ systems plus associated intellectual property. Indaba Capital, AST Revolution’s controlling sponsor, provided ongoing funding and operational support to rebuild the platform, advance product development, and position the business for this sale.
The company highlights continued scientific leadership under Chief Scientific Officer Lawrence Mertz and says Bruker is expected to be the long-term owner to commercialize the next-generation rapid antimicrobial susceptibility testing technologies.
Bruker (Nasdaq: BRKR, BRKRP) announced quarterly cash dividends for common and preferred shares.
The Board approved a $0.05 per share common stock dividend, payable January 2, 2026 to holders of record as of December 8, 2025. The Board also approved a $3.6745 per share dividend on the 6.375% Mandatory Convertible Preferred Stock, Series A, payable December 1, 2025 to holders of record as of November 15, 2025.
Bruker (Nasdaq: BRKR) will report third quarter 2025 financial results before market open on Monday, November 3, 2025.
The company will host a live conference call and webcast at 8:30 a.m. Eastern Time to discuss results and current business trends. A slide presentation will be posted to the investor website shortly before the webcast. Investors can access the webcast at https://ir.bruker.com or join by phone at 1-888-437-2685 (U.S.) or +1-412-317-6702 (international).
Pre-registration is available at https://dpregister.com/sreg/10204017/100302815b8 to receive a personalized dial-in and PIN. A telephone replay will be available beginning one hour after the call through December 3, 2025 at 1-877-344-7529 (U.S.) or +1-412-317-0088 using access code 6763149.
FAQ
What is the current stock price of Bruker (BRKR)?
What is the market cap of Bruker (BRKR)?
